Tricyclic heterocycles as bet protein inhibitors
The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
1. A compound having the structure:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.
3. A compound which is (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising the compound of claim 3 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.
5. A compound which is (4R)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising the compound of claim 5 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.
7. The compound of claim 1 which is:
8. A pharmaceutical composition comprising the compound of claim 7 and at least one pharmaceutically acceptable carrier or excipient.
9. A compound which is (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one.
10. A pharmaceutical composition comprising the compound of claim 9 and at least one pharmaceutically acceptable carrier or excipient.
11. A compound having the structure:
or a pharmaceutically acceptable salt thereof.
12. A pharmaceutically composition comprising the compound of claim 11 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.
13. A compound having the structure:
14. A pharmaceutical composition comprising the compound of claim 13 and at least one pharmaceutically acceptable carrier or excipient.